Targeted degradation technologies harness cellular protein disposal systems to eliminate disease-causing proteins that cannot be inhibited by traditional drugs.
Design bifunctional molecules that recruit E3 ligases to degrade target proteins.
Optimize linkers, warheads, and E3 binders for potent and selective degradation.
Confirm target dependency using acute protein knockdown approaches.
Understand and overcome resistance to degrader therapeutics.
Explore autophagy-targeting chimeras and RNA-targeting degraders.
Advance degraders from discovery through IND-enabling studies.
Patient Analog connects cutting-edge research with biotech intelligence infrastructure.
Explore Patient Analog